GlassScriptPhysician profile
Sanjaya K Gupta
NPI 1700904182
$316,371.62
in general payments reported to CMS, 2019-2025
18 companies · $40K in 2025
The $40K reported for 2025 was more than what 94% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $37K · 2021: $33K · 2022: $46K · 2023: $56K · 2024: $67K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $90K · Consulting Fee: $27K · Travel and Lodging: $21K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,570.00 |
| Consulting Fee | $26,900.00 |
| Travel and Lodging | $20,865.76 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,724.00 |
| Food and Beverage | $11,449.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $122,705.26 | 2019-2025 | Watchman Access System, Watchman Flx, General - Therapies |
| Zoll Respicardia, INC. | $78,568.41 | 2019-2025 | Remede System |
| Medtronic, INC. | $42,830.45 | 2021-2025 | Arctic Front Advance, Epsila Ev, Affera Mapping System |
| Medtronic Vascular, INC. | $30,671.45 | 2019-2020 | |
| Cordis US Corp. | $18,201.97 | 2024-2025 | Mynx Control, Mynx Control Venous, Mynx Venous Vcd |
| Abbott Laboratories | $15,339.64 | 2019-2025 | Perclose Proglide, Ensite, Advisor |
| Sanofi-Aventis U.S. LLC | $2,967.00 | 2020 | |
| Altathera Pharmaceuticals LLC | $2,233.04 | 2020-2025 | Sotalol Hydrochloride |
| Cardiva Medical, INC. | $1,520.24 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Biosense Webster, INC. | $515.86 | 2023-2025 | Nuvision Ice Catheter, Qdot Micro, Carto 3 |
| Impulse Dynamics (USA) INC. | $344.97 | 2021-2024 | Optimizer |
| Siemens Medical Solutions USA, INC. | $143.97 | 2023 | Acuson Sc2000 Diagnostic Ultrasound System |
| Synaptic Medical Corporation | $120.29 | 2024 | |
| Biotronik INC. | $91.91 | 2019 | |
| Irhythm Technologies, INC. | $84.67 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $18.97 | 2025 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $13.52 | 2023 | Breztri |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjaya Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.